Health · World
Merck/Moderna cancer vaccine shows 42% reduction in melanoma risk
A cancer vaccine developed by Merck and Moderna has demonstrated a 42% reduction in the risk of death or recurrence for patients with melanoma. Following the release of this data, Moderna's shares experienced a significant decline, falling over 25%. Merck's shares also saw a decrease.
How outlets across the spectrum covered it
L 0 C 2 R 0
- Centre (2): Reuters, The Globe and Mail